BioSpace News Archive

InflaRx N.V. today announced the start of the second dosing cohort of the vilobelimab and PD-1 checkpoint inhibitor, pembrolizumab, combination arm of the Phase II clinical trial in cutaneous squamous cell carcinoma (cSCC).

Our immune systems have the potential to find and destroy cancer cells. But cancer cells can be clever and develop tricks to evade the immune system.

Biofourmis announced today that Vanderbilt University Medical Center has selected Biofourmis to support a clinical study measuring the safety and efficacy of monitoring patients in a home-like outpatient setting after receiving a leading oncology drug.

Hyperfine, Inc., creator of Swoop®, the first FDA-cleared portable magnetic resonance imaging system™, is proud to announce that Queen’s University and Kingston Health Sciences Centre are deploying a Swoop system as part of their health services benefitting six communities located in the James Bay and Hudson Bay Area.

Fate Therapeutics, Inc. today announced that the Company will host a conference call and live audio webcast on Monday, February 28, 2022 at 5:00 PM ET to report its fourth quarter and full year 2021 financial results and provide a corporate update.

BioVaxys Technology Corp. announced today that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine, demonstrate that the vaccine does not bind to the Angiotensin Converting Enzyme-2 (ACE2) receptor.

Theranica, today announced the publication of a new peer-reviewed study published in Pain Medicine, examining the use of combining Nerivio’s® Guided Imagery, Education and Relaxation (GIER) in-app optional behavioral intervention feature for acute treatment of migraine.

Today, CELLINK, a BICO Group company (Nasdaq Stockholm: BICO) and a global leader in developing 3D bioprinting technologies which is expected to bridge the current gap and allow unlimited supply of life saving organs and CollPlant Biotechnologies (Nasdaq: CLGN) announced they have signed a collaboration agreement.

Allogene Therapeutics, Inc. today announced that it will report fourth quarter and year-end 2021 financial results on Wednesday, February 23, 2022 after the close of the market.

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the publication of a peer-reviewed study in the Journal of Wound Care evaluating the cost-effectiveness of the Company’s PURION® processed dehydrated human amnion/chorion membrane (DHACM) allografts (EPIFIX®) compared with standard of care for treating lower extremity diabetic ulcers (LEDUs), including diabetic foot ulcers (DFUs).